Clinical data | |
---|---|
Trade names | Vumon |
Other names | VM-26 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a692045 |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | >99% |
Metabolism | Hepatic (CYP2C19-mediated) |
Elimination half-life | 5 hours |
Excretion | Renal and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.045.286 |
Chemical and physical data | |
Formula | C32H32O13S |
Molar mass | 656.66 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Teniposide (trade name Vumon) is a chemotherapeutic medication[1] used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer.[2] It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.[3]